Trial Profile

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine, and Dacarbazine (APVD) for Patients With Untreated Classical Hodgkin Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dacarbazine (Primary) ; Doxorubicin (Primary) ; Pembrolizumab (Primary) ; Vinblastine (Primary)
Indications Hodgkin's disease
Focus Adverse reactions; Therapeutic Use

10 Dec 2024 Results assessing overall rates of potential delayed irAEs, as defined below, in our cohort of 50 patients treated with pembrolizumab and AVD (APVD), presented at the 66th American Society of Hematology Annual Meeting and Exposition.
10 Dec 2024 Results assessing updated clinical data full 50-patient study including interim and end of treatment (EOT) MRD testing by PhasED-Seq, presented at the 66th American Society of Hematology Annual Meeting and Exposition.
12 Dec 2023 Results(n=50) presented at the 65th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com